March 4, 2026 — Leads & Copy — Stevanato Group S.p.A. (NYSE: STVN) has released its financial results for the fourth quarter and full year 2025, reporting a revenue increase of 5% to €346.5 million for the fourth quarter, with high-value solutions representing 49% of total revenue.
The company’s gross profit margin increased 120 basis points to 30.9%, and adjusted EBITDA margin increased 70 basis points to 28.2% for the same period. Diluted earnings per share were reported at €0.17, and adjusted diluted earnings per share were €0.18 for the fourth quarter of 2025.
For the full fiscal year 2025, Stevanato Group reported a 7% increase in revenue, reaching €1.186 billion, with high-value solutions accounting for 46% of the total revenue. The gross profit margin increased 160 basis points to 29.0%, and the adjusted EBITDA margin also increased by 160 basis points to 25.1% for the fiscal year.
Diluted earnings per share for fiscal year 2025 grew by 19% to €0.51, while adjusted diluted earnings per share increased by 13% to €0.54.
The company is setting its fiscal 2026 guidance, anticipating revenue between €1.26 billion and €1.29 billion, adjusted EBITDA ranging from €331.8 million to €346.9 million, and adjusted diluted EPS between €0.59 and €0.63.
According to the press release, the Biopharmaceutical and Diagnostic Solutions (BDS) Segment experienced a 10% revenue increase, driven by a 31% increase in high-value solutions, representing 56% of BDS Segment revenue. The Engineering Segment saw a 23% decrease in revenue.
As of December 31, 2025, the company held cash and cash equivalents of €130.6 million, with a net debt of €337.7 million. Capital expenditures for fiscal year 2025 totaled €294.9 million. Cash flow from operating activities for the same period was €286.1 million. The company reported €18.4 million of positive free cash flow for the year.
Franco Stevanato, Chief Executive Officer, noted that biologics remain an important tailwind, with GLP1s representing approximately 19% to 20% of total company revenue in 2025. He stated the company’s success is rooted in its history as a trusted partner, its global footprint, and the quality of its products.
The company believes it has adequate liquidity to fund its strategic priorities over the next twelve months.
Stevanato concluded, “We enter 2026 with positive momentum and a clear focus on disciplined execution. We operate in attractive, growing end markets with favorable secular tailwinds. Innovation across the industry continues to advance patient care and we remain mission critical to the delivery of innovative biologics. Biologics are expected to remain our fastest growing end market and a key driver to top-line growth and margin expansion as we continue to move up the value chain. In Latina and Fishers, we expect to increasingly benefit from improved utilization, efficiencies, and operating leverage, as we support our customers with quality and reliability.”
Source: Stevanato Group
